Dwight Thibodeaux
Optometrist · Santa Fe, NMNPI 1962516039
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 173 payments — averaging $30.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$1K
- AbbVie$1K
- Dompe US, Inc.$529
- Alcon$426
- Sight Sciences, Inc.$358
- Bausch & Lomb, A Division Of Bausch Health US, LLC$352
- plus $1K from 14 others
What the payments were for
- Food & beverage$5,295100%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 36 | $1,102 |
| AbbVie(2 entities) | 43 | $1,078 |
| Dompe US, Inc. | 12 | $529 |
| Alcon | 11 | $426 |
| Sight Sciences, Inc. | 4 | $358 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 16 | $352 |
| Sun Pharmaceutical Industries Inc. | 16 | $294 |
| Aerie Pharmaceuticals, Inc. | 3 | $231 |
| Shire North American Group Inc | 4 | $140 |
| Tarsus Pharmaceuticals, Inc. | 1 | $121 |
| Coopervision Inc. | 5 | $109 |
| Apellis Pharmaceuticals, Inc. | 1 | $109 |
| Mallinckrodt Hospital Products Inc. | 4 | $95 |
| Johnson & Johnson Vision Care, Inc. | 5 | $93 |
| ABB Con-cise Optical Group LLC | 2 | $80 |
| Novartis | 3 | $67 |
| Kala Pharmaceuticals, Inc. | 3 | $43 |
| Biotissue Holdings Inc. | 2 | $40 |
| Harrow Eye, LLC | 1 | $28 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Oxervate$352
- INFUSE$328
- MIEBO$250
- XIIDRA$250
- TearCare SmartLid$227
- TEARCARE(TM) (2.2) SYSTEM KIT$227
- Rhopressa$211
- Rocklatan$211
- Precision7$149
- VUITY$125
- XDEMVY$121
- DURYSTA$117
- OMNI(R) SURGICAL SYSTEM (US)$114
- Precision 1$112
- Syfovre$109
How this compares
$5,315 in reported general payments places this provider in the 95th percentile of 228 optometrist providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 61 | $33,143 |
| XiidraLifitegrast | 16 | $18,635 |
| VyzultaLatanoprostene Bunod | 40 | $16,474 |
| RestasisCyclosporine | 16 | $16,461 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $10,934 |
| Cyclosporine | 15 | $7,977 |
| Latanoprost | 357 | $6,215 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 18 | $5,561 |
| Brinzolamide | 23 | $4,534 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $3,576 |
| Travoprost | 21 | $3,267 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 142 | $2,607 |
| Brimonidine Tartrate | 70 | $1,950 |
| Dorzolamide Hcl | 131 | $1,840 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $1,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis | $1,078 | $49,60477 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,102 | $35,10956 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $231 | $10,93419 claims |
| AlconSimbrinza | $426 | $5,56118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 228 optometrist providers in New Mexico.
Other optometrist in Santa Fe
- David ViseSanta Fe$8K
- Paul TachauSanta Fe$4K
- Shinichi HamashigeSanta Fe$3K
- Jaqueline IsquierdoSanta Fe$2K
- Micayla Fisher-IvesSanta Fe$1K
- Vanlin BotwinSanta Fe$946
- Keith BarkerClovis$52K
- Elysia IsonShiprock$37K
- David BabingtonAlbuquerque$8K
- Nicolette EstradaAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.